Does 18F FDG PET/CT paramaters predict histopathologic response to the neoadjuvant therapy in patients with non-small cell lung cancer?

Journal Title: Medical Science and Discovery - Year 2018, Vol 5, Issue 10

Abstract

Objective: Progression-free and overall survival are better correlated with metabolically active tumor volume (MTV) and total lesion glycolysis (TLG), as compared to the maximum standardized uptake value (SUVmax) in NSCLC patients. In this study, we aimed to evaluate the correlation between the PET-CT parameters and histopathologic tumor regression score in non-small cell lung cancer(NSCLC) patients after treatment with neoadjuvant chemotherapy.(1) Methods: This retrospective study evaluated stage III lung cancer patients who were treated with neoadjuvant chemotherapy followed by surgical resection at a single institution between 2014 and 2018. The 3-dimensional volumes of interest were drawn in primary tumor and largest lymph node on the pretreatment examination and corresponding location on the post-treatment examination to obtain a pre- and post-treatment SUVmax, SUVmean, MTV and TLG. All hematoxylin- and eosin-stained surgery specimens were assessed based on a 4-tiered scale. Results: Patients who had lower than 10% histologic response established higher values of SUVmax, in tumor as compared to good responders in basal PET CT assessment (p:0.014). Patients who established higher than 10% pathologic response showed higher reduction rates in terms of SUVmax (p:0.002), mean tumor volume (p:0.024), and total lesion glycolysis (p:0.009). The overall survival for patients with <10% histologic response was 15.26 months while the patients with good histologic response had 35.36 months and the difference was statistical significance (p<0.001). Due to univariate analysis, the higher SUVmax, TLG and MTV reduction have been found in association with better overall survival. Conclusion: PET CT parameters may be useful to predict histopathologic response for NSCLC patients who received neoadjuvant chemotherapy.

Authors and Affiliations

Ozlem Yersal, Arzu Cengic, Salih Cokpinar, Nesibe Kahraman Cetin, Nezih Meydan, Sabri Barutca, Serdar Sen

Keywords

Related Articles

Adult nasopharyngeal hairy polyp presenting with middle ear effusion

ABSTRACTInroduction: Hairy polyp is a relatively uncommon congenital mass mainly seen in naso-oropharynx. It has been also called as choristoma owing to its bigerminal composition and unexpected location.  It is almost a...

Dental sedation by anesthesiologist or dentists: A view from Turkey

Background: Except conscious sedation (with nitrous oxide/oxygen), sedation of dental patient has been applied by anesthesiologists in Turkey. But little is known about Anesthesiology and Reanimation Specialist (ARS)’s a...

Anomalous origin of Left Coronary Artery from Pulmonary Artery; Congenital Anomaly Presenting with Dyspnea. A rare Case Study

Anomalous origin of left coronary artery from pulmonary artery (ALCAPA) is rare congenital anomaly. Most of these patients die is infancy. Presentation in adulthood is very rare. Clinical manifestation in teenagers or yo...

Shoulder ganglion cysts in MRI: accompanying tendon pathologies and labral lesions

Objective:  The aim of this study was to investigate shoulder tendon pathologies and labral lesions that accompanied with ganglion cysts on the shoulder via magnetic resonance imaging (MRI). Material and Metho...

The significance of lower extremity FDG PET/CT imaging in patients with unknown primary tumor

If a suspicious finding for primary site of an unknown primary tumor (UPT) is found in limited whole-body FDG PET/CT imaging area, imaging of lower extremities is generally not performed in routine practice. This approac...

Download PDF file
  • EP ID EP520302
  • DOI 10.17546/msd.470198
  • Views 45
  • Downloads 0

How To Cite

Ozlem Yersal, Arzu Cengic, Salih Cokpinar, Nesibe Kahraman Cetin, Nezih Meydan, Sabri Barutca, Serdar Sen (2018). Does 18F FDG PET/CT paramaters predict histopathologic response to the neoadjuvant therapy in patients with non-small cell lung cancer?. Medical Science and Discovery, 5(10), 344-349. https://europub.co.uk/articles/-A-520302